Egypt Hepatitis C Treatment Drugs Market Projected to be Dominated by the Fixed-Combination Therapy Through 2027

The increasing awareness regarding the effective drugs available for the treatment of Hepatitis C and the growing number of drug approvals are primarily driving the growth of the Egypt Hepatitis C treatment market.

According to TechSci report on, “Egypt Hepatitis C Treatment Drug Market - Region, Competition Forecast & Opportunities, 2027”, the Egypt Hepatitis C treatment drug market is projected to witness lucrative growth and record an impressive CAGR over the forecast period of 2023-2027. The market growth can be attributed to the rising instances of blood transfusion disorders and the increasing cases of hospital-acquired infections (HAIs). Hepatitis C is a condition in which liver tissues become inflamed due to the contamination of blood or other body fluids from an infected person. According to a survey, Hepatitis C is one of the most infectious causes of death, exceeding HIV, hepatitis B, and TB combined. Egypt has the highest prevalence of hepatitis C in the world. The HCV prevalence rate has reached to 13% of the population accounting for approx. 12 million Egyptians. Out of these, 8 million people are living with chronic hepatitis. Moreover, a significant number of patients dealing with hepatitis C are more prone to develop liver cancer or liver cirrhosis. To deal with such severe disorders, several market leaders are introducing technologically advanced therapeutic products for the treatment of hepatitis C. Earlier, the cure for hepatitis C was not available, but with the launch of products Sovaldi and Harvoni in 2013 and 2014, respectively. This has resulted in an increased number of patients opting for hepatitis C treatment, thereby fueling the market growth. Apart from this, the increasing number of drug approvals by the governments and concerned authorities and growing access to medicines are providing a positive outlook to the market growth. In addition, the constantly improving healthcare and sanitation and the rising awareness about the advanced treatments available for the diseases are providing thrust to the market. Furthermore, Egypt is constantly spending on their healthcare, and the governments are providing treatment drugs at a subsidized rate to help more patients avail the quality treatment. This eventually is anticipated to propel the Egypt hepatitis C treatment drug market in the coming years

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on "EGYPT HEPATITIS C TREATMENT DRUGS MARKET"

The Egypt Hepatitis C treatment drug market is segmented by disease type, drug class, distribution channel, competitive landscape, and regional distribution. Based on the disease type, the market is differentiated between acute and chronic. Among these, the chronic Hepatitis C segment is expected to hold a significant market share over the forecast period. This is primarily because 70-75 percent of acute Hepatitis C tend to develop into a chronic form. Moreover, the chronic form is a long-term illness and may require lifetime treatment. As a result, this segment is majorly contributing to the Egypt Hepatitis C treatment drug market

By drug class, the market is segmented into combination therapy, protease inhibitors, polymerase inhibitors, immunomodulators, antiviral medications, and others. In terms of drug class, the fixed-dose combination segment is projected to hold a considerable market share in the coming years as fixed-dose combination therapy is extremely efficient for the treatment of the disorder. The high effectiveness of this therapy across all genotypes of Hepatitis C and the presence of major drugs in this segment have resulted in more adoption of fixed-combination therapy.

Based on distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment is anticipated to hold a significant market share in the coming years due to the growing instances of hospitalizations, improved services, and easy accessibility. The availability of these drugs at hospital pharmacies facilitates greater safety and guidance regarding the administration of the drug. However, online pharmacies are also projected to register a higher CAGR over the coming years due to the availability of hepatitis C treatment drugs at a discounted rate and convenience of ordering medicines at the convenience of home.

A list of major market players of the Egypt Hepatitis C treatment drug market market includes:

• GlaxoSmithKline, Plc.
• Gilead Sciences, Inc.
• Johnson & Johnson
• AbbVie, Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche AG

DOWNLOAD FREE SAMPLE REPORT

Customers can also request for 10% free customization on this report.


“Increasing availability of advanced Hepatitis C drugs and rising number of patients getting highly effective therapeutics has resulted in an increased number of positive outcomes, which is boosting the market growth in the region. Besides, R&D in the medical sector, new product launches in the country, and presence of large patient pool undergoing the treatment are propelling the hepatitis C treatment drug market in the country. Apart from this, the market is semi-consolidated. The market players are advised to expand their portfolio of hepatitis C therapeutics along with focusing on tapping the untapped areas by strengthening their distribution channel.,” said Mr. Karan Chechi, Research Director, TechSci Research, a research-based Egypt management consulting firm.

“Egypt Hepatitis C Treatment Drug Market By Disease Type (Acute v/s Chronic), By Drug Class (Combination Therapy, Protease Inhibitors, Polymerase Inhibitors, Immunomodulators, Antiviral Medications, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Region, Competition Forecast & Opportunities, 2027” has evaluated the future growth potential of global Hepatitis C treatment drug market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the global Hepatitis C treatment drug market.

Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com